Eupraxia Pharmaceuticals (EPRX) Receivables - Net (2022 - 2025)
Eupraxia Pharmaceuticals (EPRX) posted quarterly Receivables - Net of $716095.0 for Q4 2025, up 177.48% year-over-year from $258074.0 in Q4 2024, and up 177.48% quarter-over-quarter from $258074.0 in Q4 2024.
Eupraxia Pharmaceuticals (EPRX) Receivables - Net (2022 - 2025) Analysis & Trends
Eupraxia Pharmaceuticals (EPRX) has reported Receivables - Net for 4 consecutive years, with $716095.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables - Net rose 177.48% year-over-year to $716095.0; the TTM figure through Dec 2025 stood at $716095.0 (up 177.48% YoY), while the FY2025 annual figure was $716095.0, up 177.48% from the prior year.
- Receivables - Net grew to $716095.0 in Q4 2025 per EPRX's latest filing, from $258074.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $716095.0 in Q4 2025 and bottomed at $13892.0 in Q4 2022.
- Historically, Receivables - Net has averaged $285452.5 across 4 years, with a median of $205911.5 in 2023.
- Annual changes were most pronounced in 2023 — Receivables - Net soared 1006.74% — and 2024, when it jumped 67.85%.
- Eupraxia Pharmaceuticals' Receivables - Net stood at $13892.0 in 2022, then jumped by 1006.74% to $153749.0 in 2023, then soared by 67.85% to $258074.0 in 2024, then jumped by 177.48% to $716095.0 in 2025.
- Business Quant data shows EPRX's Receivables - Net at $716095.0 in Q4 2025, $258074.0 in Q4 2024, and $153749.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Eupraxia Pharmaceuticals | 381.11 Mn | 379.51 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 716,095.00 |
| Dec 31, 2025 | 716,095.00 |
| Dec 31, 2024 | 258,074.00 |
| Dec 31, 2024 | 258,074.00 |
| Dec 31, 2023 | 153,749.00 |
| Dec 31, 2023 | 153,749.00 |
| Dec 31, 2022 | 13,892.00 |
| Dec 31, 2022 | 13,892.00 |